We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.60 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 3.59%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 2.54%.
DGX’s Q4 Estimates
The Zacks Consensus Estimate for revenues is pegged at $2.75 billion, indicating an increase of 4.8% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS suggests a 5.4% rise to $2.35.
Estimate Revision Trend Ahead of DGX’s Q4 Earnings
Estimates for Quest Diagnostics’ Q4 earnings have remained stable in the past 30 days.
Here’s a brief review of the company’s performance leading up to the announcement.
Factors Likely to Influence DGX’s Q4 Results
Quest Diagnostics’ core Diagnostics Information Services (“DIS”) business is expected to have delivered strong revenues in the fourth quarter of 2025, driven by its organic growth in its physician, hospital and consumer channels. The company’s solid commercial execution is likely to have led physicians to order more tests per requisition, sustaining the demand momentum for its clinical solutions.
Last quarter, DGX completed the acquisition of select clinical testing assets from Fresenius Medical Care. Under a separate enterprise agreement, Quest also began to roll out clinical lab testing to Fresenius Medical Care's dialysis centers, which serve about 200,000 dialysis patients annually in the United States. Together, these developments might have favored physician channel revenues in the fourth quarter. Our model assumes a 2.8% acquired contribution to DIS revenues in the to-be-reported quarter.
In Advanced Diagnostics, DGX is expected to have generated robust revenues across several clinical areas, including advanced cardiometabolic, endocrine and autoimmune disease testing with its ANAlyzeR autoimmune solution. Growth in Brain Health might have been led by AD-detect blood tests for assessing Alzheimer's disease risk. In oncology, Quest Diagnostics is likely to have continued ramping up its commercial outreach to drive market adoption of the Haystack MRD test.
Collaborative Lab Solutions might have contributed to growth in the hospital channel. Alongside reference testing and outreach laboratory acquisitions, Quest Diagnostics continued to provide hospitals with strategic access to leading diagnostic innovations without the need to operate in-house laboratories. Last quarter, Quest Diagnostics and Corewell Health, a leading health system, announced plans to establish a laboratory services joint venture in Michigan, featuring a state-of-the-art facility designed to serve the entire state.
Quest Diagnostics Incorporated Price and EPS Surprise
An enhanced questhealth.com platform is likely to have contributed to strong fourth-quarter revenues. Through partnerships with leading consumer health and wellness brands, Quest Diagnostics is delivering its broad test menu and advanced technology directly within established consumer platforms, which might have supported growth in the consumer-initiated testing channel in the fourth quarter.
Going by our model, the company’s DIS revenues are likely to increase 4.7% year over year in the fourth quarter of 2025.
In terms of operational excellence, Quest Diagnostics must have continued to expand the use of automation, robotics, and AI to improve quality, customer and employee experiences and productivity. Last quarter, Quest announced Epic as the technology partner for Project Nova, a multiyear order-to-cash transformation. This development should have contributed to the company’s top-line growth. Our model expects the company’s operating income (non-GAAP basis) to increase 11.6% year over year in the fourth quarter of 2025.
What Our Model Unveils for DGX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Quest Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter 2025 results soon.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS suggests a decline of 13.9% from the year-ago quarter’s figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +2.30% and a Zacks Rank #2 at present. The company is slated to release second-quarter fiscal 2026 results on Feb. 5.
CAH’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.36%. The Zacks Consensus Estimate for fiscal second-quarter EPS implies a year-over-year increase of 20.7%.
Merit Medical Systems (MMSI - Free Report) currently has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is expected to release fourth-quarter 2025 results soon.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for fourth-quarter EPS implies an increase of 3.2% from the year-ago quarter’s figure.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's How Quest Diagnostics Is Placed Ahead of Q4 Earnings
Key Takeaways
Quest Diagnostics (DGX - Free Report) is set to release fourth-quarter 2025 results on Feb. 10, before the market opens.
The renowned diagnostics provider posted adjusted earnings per share (EPS) of $2.60 in the last reported quarter, which surpassed the Zacks Consensus Estimate by 3.59%. The company topped earnings estimates in each of the trailing four quarters, the average surprise being 2.54%.
DGX’s Q4 Estimates
The Zacks Consensus Estimate for revenues is pegged at $2.75 billion, indicating an increase of 4.8% from the year-ago reported figure.
The Zacks Consensus Estimate for EPS suggests a 5.4% rise to $2.35.
Estimate Revision Trend Ahead of DGX’s Q4 Earnings
Estimates for Quest Diagnostics’ Q4 earnings have remained stable in the past 30 days.
Here’s a brief review of the company’s performance leading up to the announcement.
Factors Likely to Influence DGX’s Q4 Results
Quest Diagnostics’ core Diagnostics Information Services (“DIS”) business is expected to have delivered strong revenues in the fourth quarter of 2025, driven by its organic growth in its physician, hospital and consumer channels. The company’s solid commercial execution is likely to have led physicians to order more tests per requisition, sustaining the demand momentum for its clinical solutions.
Last quarter, DGX completed the acquisition of select clinical testing assets from Fresenius Medical Care. Under a separate enterprise agreement, Quest also began to roll out clinical lab testing to Fresenius Medical Care's dialysis centers, which serve about 200,000 dialysis patients annually in the United States. Together, these developments might have favored physician channel revenues in the fourth quarter. Our model assumes a 2.8% acquired contribution to DIS revenues in the to-be-reported quarter.
In Advanced Diagnostics, DGX is expected to have generated robust revenues across several clinical areas, including advanced cardiometabolic, endocrine and autoimmune disease testing with its ANAlyzeR autoimmune solution. Growth in Brain Health might have been led by AD-detect blood tests for assessing Alzheimer's disease risk. In oncology, Quest Diagnostics is likely to have continued ramping up its commercial outreach to drive market adoption of the Haystack MRD test.
Collaborative Lab Solutions might have contributed to growth in the hospital channel. Alongside reference testing and outreach laboratory acquisitions, Quest Diagnostics continued to provide hospitals with strategic access to leading diagnostic innovations without the need to operate in-house laboratories. Last quarter, Quest Diagnostics and Corewell Health, a leading health system, announced plans to establish a laboratory services joint venture in Michigan, featuring a state-of-the-art facility designed to serve the entire state.
Quest Diagnostics Incorporated Price and EPS Surprise
Quest Diagnostics Incorporated price-eps-surprise | Quest Diagnostics Incorporated Quote
An enhanced questhealth.com platform is likely to have contributed to strong fourth-quarter revenues. Through partnerships with leading consumer health and wellness brands, Quest Diagnostics is delivering its broad test menu and advanced technology directly within established consumer platforms, which might have supported growth in the consumer-initiated testing channel in the fourth quarter.
Going by our model, the company’s DIS revenues are likely to increase 4.7% year over year in the fourth quarter of 2025.
In terms of operational excellence, Quest Diagnostics must have continued to expand the use of automation, robotics, and AI to improve quality, customer and employee experiences and productivity. Last quarter, Quest announced Epic as the technology partner for Project Nova, a multiyear order-to-cash transformation. This development should have contributed to the company’s top-line growth. Our model expects the company’s operating income (non-GAAP basis) to increase 11.6% year over year in the fourth quarter of 2025.
What Our Model Unveils for DGX
Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold), along with a positive Earnings ESP, has a higher chance of beating estimates, which is not the case here, as you can see.
Earnings ESP: Quest Diagnostics has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Top MedTech Picks
Here are some medical stocks worth considering, as these have the right combination of elements to post an earnings beat this time around:
Veracyte (VCYT - Free Report) has an Earnings ESP of +7.98% and a Zacks Rank #2 at present. The company is expected to release fourth-quarter 2025 results soon.
VCYT’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 45.12%. The Zacks Consensus Estimate for the company’s fourth-quarter EPS suggests a decline of 13.9% from the year-ago quarter’s figure.
Cardinal Health (CAH - Free Report) has an Earnings ESP of +2.30% and a Zacks Rank #2 at present. The company is slated to release second-quarter fiscal 2026 results on Feb. 5.
CAH’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 9.36%. The Zacks Consensus Estimate for fiscal second-quarter EPS implies a year-over-year increase of 20.7%.
Merit Medical Systems (MMSI - Free Report) currently has an Earnings ESP of +2.09% and a Zacks Rank #2. The company is expected to release fourth-quarter 2025 results soon.
MMSI’s earnings topped estimates in each of the trailing four quarters, the average surprise being 14.1%. The Zacks Consensus Estimate for fourth-quarter EPS implies an increase of 3.2% from the year-ago quarter’s figure.